Compare
Nektar Therapeutics vs Integrated Biopharma Inc vs Agios Pharmaceuticals, Inc. vs Q32 Bio Inc.
| Latest fiscal year | Nektar Therapeutics NKTR | Integrated Biopharma Inc INBP | Agios Pharmaceuticals, Inc. AGIO | Q32 Bio Inc. QTTB |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-06-30 | 2025-12-31 | 2025-12-31 |
| Revenue | $55.23M | $54.35M | $54.03M | $53.74M |
| Revenue growth (YoY) | -43.9% | +8.0% | +48.0% | n/a |
| Gross margin | n/a | 10.2% | 88.3% (computed) | n/a |
| Operating margin | -253.7% | 3.7% | -873.9% | 31.5% |
| Net margin | -297.1% | 1.5% | -764.0% | 55.5% |
| Net income | -$164.08M | $808.0K | -$412.78M | $29.82M |
| EPS (Diluted) | -$9.73 | $0.03 | -$7.12 | $2.42 |
| Operating cash flow | -$208.51M | $2.06M | -$372.98M | -$33.54M |
| Free cash flow | -$208.68M | $1.87M | -$377.29M | -$33.54M |
| Cash & equivalents | $15.12M | $3.62M | $89.13M | $48.30M |
| Total assets | $280.41M | $24.90M | $1.30B | $61.78M |
| Total liabilities | $190.57M | $4.58M | $104.11M | $19.76M |
| Shareholders' equity | $89.83M | $20.32M | $1.19B | $42.01M |
| Return on year-end equity | -182.6% | 4.0% | -34.6% | 71.0% |
| Shares outstanding | 20.38M | 31.06M | 58.45M | 12.86M |
Revenue, most recent five fiscal years
| Fiscal year | Nektar Therapeutics | Integrated Biopharma Inc | Agios Pharmaceuticals, Inc. | Q32 Bio Inc. |
|---|---|---|---|---|
| Latest | $55.23M Ended 2025-12-31 | $54.35M Ended 2025-06-30 | $54.03M Ended 2025-12-31 | $53.74M Ended 2025-12-31 |
| 1 year earlier | $98.43M Ended 2024-12-31 | $50.32M Ended 2024-06-30 | $36.50M Ended 2024-12-31 | $0 Ended 2024-12-31 |
| 2 years earlier | $90.12M Ended 2023-12-31 | $50.67M Ended 2023-06-30 | $26.82M Ended 2023-12-31 | -$6.65M Ended 2023-12-31 |
| 3 years earlier | $92.06M Ended 2022-12-31 | $56.25M Ended 2022-06-30 | $14.24M Ended 2022-12-31 | n/a |
| 4 years earlier | $101.91M Ended 2021-12-31 | $63.56M Ended 2021-06-30 | $0 Ended 2021-12-31 | n/a |